Manufacturing, Packaging & Detailing Market Research Reports & Industry Analysis
Current Good Manufacturing Practices (cGMPs) refers to the regulations enforced by the FDA. The cGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities.
Adherence to the cGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. This includes establishing strong quality management systems, obtaining appropriate quality raw materials, establishing robust operating procedures, detecting and investigating product quality deviations, and maintaining reliable testing laboratories. This formal system of controls at a pharmaceutical company, if adequately put into practice, helps to prevent instances of contamination, mix-ups, deviations, failures, and errors. This assures that drug products meet their quality standards.
The cGMP requirements were established to be flexible in order to allow each manufacturer to decide individually how to best implement the necessary controls by using scientifically sound design, processing methods, and testing procedures. The flexibility in these regulations allows companies to use modern technologies and innovative approaches to achieve higher quality through continual improvement.
- Use of RFID in serialized unique packaging numbering to authenticate and check for recall/expiry status.
- Use of X-ray and metal detection systems to detect glass, stone, bone, rubber and other contaminants
- Use of checkweighers and sorters
- Use of baggers capable of handling, opening and sealing bags manufactured from specialist sterile films and papers.
- Use of quality control labeling systems
It is important to note that cGMPs are minimum requirements. Many pharmaceutical manufacturers are already implementing comprehensive, modern quality systems and risk management approaches that exceed these minimum standards. This is important because a consumer cannot detect through smell, touch, or sight if a drug product is safe or if it will work.
Manufacturing, Packaging & Detailing Industry Research & Market Reports
-
Nanocapsules
... 6.3% over the analysis period 2024-2030. Oncology, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in ... Read More
-
Alopecia Drugs
... CAGR of 5.5% over the analysis period 2024-2030. Topical Drugs, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$8.4 Billion by the end of the analysis ... Read More
-
Antifungal Drugs
... CAGR of 4.2% over the analysis period 2024-2030. Azoles, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$10.7 Billion by the end of the analysis period. ... Read More
-
Healthcare Analytical Testing Services
... 2030, growing at a CAGR of 9.7% over the analysis period 2024-2030. Bioanalytical Testing Services, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$2.6 Billion by ... Read More
-
Chronic Kidney Disease (CKD) Drugs
... Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Antihypertensives, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$6.0 Billion by ... Read More
-
Life Sciences BPO
... at a CAGR of 6.5% over the analysis period 2024-2030. Pharmaceutical Outsourcing Services, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$281.8 Billion by the end ... Read More
-
Pharmaceutical Excipients
... CAGR of 4.5% over the analysis period 2024-2030. Organic Chemicals, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$9.8 Billion by the end of the analysis ... Read More
-
Global Z-L-Valine NCA Market Report, History and Forecast 2020-2031
... 4.78% during the forecast period 2025-2031. North American market for Z-L-Valine NCA was valued at $ 16.62 million in 2024 and will reach $ 23.62 million by 2031, at a CAGR of 5.33% during the ... Read More
-
Pharmaceutical Filtration
... CAGR of 17.2% over the analysis period 2024-2030. Membrane Filters, one of the segments analyzed in the report, is expected to record a 21.2% CAGR and reach US$19.6 Billion by the end of the analysis ... Read More
-
Hormone Replacement Therapy (HRT)
... 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. Estrogen Hormone Replacement Therapy, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$24.2 Billion ... Read More
-
Orphan Drugs
... CAGR of 12.0% over the analysis period 2024-2030. Biologic Drugs, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$308.5 Billion by the end of the analysis ... Read More
-
Active Pharmaceutical Ingredients (API)
... 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Innovative, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$240.8 Billion by the end ... Read More
-
Ginseng
... 10.2% over the analysis period 2024-2030. Asian Ginseng, one of the segments analyzed in the report, is expected to record a 10.0% CAGR and reach US$11.2 Billion by the end of the analysis period. Growth ... Read More
-
Pharmaceutical Packaging
... CAGR of 8.2% over the analysis period 2024-2030. Plastics & Polymers, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$114.0 Billion by the end of the ... Read More
-
Non-alcoholic Steatohepatitis (NASH)
... at a CAGR of 55.7% over the analysis period 2024-2030. Vitamin E & Pioglitazone, one of the segments analyzed in the report, is expected to record a 45.3% CAGR and reach US$59.7 Billion by the ... Read More
-
Vial Adaptors for Reconstitution Drug
... Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Polycarbonate, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$1.3 Billion by ... Read More
-
Anti-Platelet Agents
... CAGR of 6.7% over the analysis period 2024-2030. Hospital Pharmacies, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$2.3 Billion by the end of the analysis ... Read More
-
Parkinson’s Disease Drugs
... at a CAGR of 6.5% over the analysis period 2024-2030. Oral, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$4.6 Billion by the end of the ... Read More
-
Epilepsy Drugs
... CAGR of 3.8% over the analysis period 2024-2030. First Generation, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$1.6 Billion by the end of the analysis ... Read More
-
Healthcare Contract Development and Manufacturing Organization
... reach US$547.1 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Contract Manufacturing, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach ... Read More
-
Pharmaceutical Cartridges
... CAGR of 6.8% over the analysis period 2024-2030. Glass, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$2.0 Billion by the end of the analysis period. ... Read More
-
Pharmaceutical Membrane Filtration
... at a CAGR of 10.5% over the analysis period 2024-2030. Filters, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$11.7 Billion by the end of the ... Read More
-
Pharmaceutical Robots
... CAGR of 7.6% over the analysis period 2024-2030. Traditional Robots, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$224.1 Million by the end of the analysis ... Read More
-
Pharmerging
... 9.7% over the analysis period 2024-2030. Pharmaceutical, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in ... Read More
-
Semi-Automatic Filling Equipment
... at a CAGR of 6.6% over the analysis period 2024-2030. Food & Beverages, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$2.0 Billion by the end ... Read More
Research Assistance
